From medical device to wellness wearable
Over-the-counter glucose monitors are continuous glucose monitoring devices that can be bought without a prescription and used as everyday wearables for metabolic health tracking, giving real-time feedback on how food, exercise, stress, and sleep influence blood sugar trends for people with and without diabetes.
The core shift is simple and radical: a continuous glucose monitor (CGM) on your arm now behaves like a consumer wearable, app-connected and pitched as a way to understand your body in real time. Ultrahuman’s new M2 Live platform, announced on June 18, sits squarely in this movement by pairing Abbott’s over-the-counter Lingo CGM with a subscription-based metabolic health ecosystem that drops the prescription hurdle.
This is not a niche tweak. The FDA’s clearance of Dexcom’s Stelo as the first OTC CGM and Abbott’s clearance of Lingo opened a new market where glucose tracking wearables are sold as lifestyle tools, not only as treatment companions. That democratization is exciting, but it also invites hype, confusion, and new risks for users who are not living with diabetes.
Ultrahuman M2 Live: Glucose tracking as a subscription lifestyle
Ultrahuman’s M2 Live is the clearest signal that over-the-counter glucose monitors have crossed into mainstream wellness. The platform uses Abbott’s Lingo CGM, which is available OTC for adults who are not on insulin, and combines those readings with streams of data from the Ultrahuman Ring and other sources to generate metabolic insights and scores.
A subscription at USD 99 (approx. RM460) per month includes two CGM sensors, positioning M2 Live in the same psychological price band as premium fitness wearables but with a far more invasive sensor model. Each Lingo biosensor can be worn for up to 14 days, though only 77.1% lasted the full period in one study, while 22.9% did not when used according to labeling. That is a quotable reminder that this is still medical hardware, not a simple wristband.
Ultrahuman promises that M2 Live helps people understand how their body responds to food, exercise, stress, and sleep in real time. In other words, users are paying not just for continuous glucose monitoring, but for a narrative about their metabolic health stitched together by Jade, the company’s AI system, and wrapped in daily scores for metabolism, food, and fueling.
Who really benefits from OTC CGMs?
Despite the wellness marketing, the clearest clinical value of over-the-counter glucose monitors still lies with people on the metabolic brink. The CDC estimates that 115.2 million adults have prediabetes and 40.1 million people have diagnosed or undiagnosed diabetes. A 2026 systematic review found that CGM use was linked with lower mean glucose in non-diabetic users, with benefits concentrated among people with prediabetes and no significant effect on BMI.
Devices like Stelo are explicitly designed for adults who do not use insulin, including some people with diabetes and people without diabetes seeking diet and exercise feedback. In that group, continuous feedback can support more consistent routines: fewer massive post-meal spikes, smarter training plans, tighter sleep schedules. For them, metabolic health tracking is less about curiosity and more about course correction before chronic disease locks in.
For healthy users with stable glucose, the story is weaker. The same data that light up dashboards may not translate into meaningful long-term health gains. Glucose spikes are not inherently bad, and over-focusing on them risks pathologizing normal physiology. More numbers, in other words, are not automatically more health.
Democratized access, messy interpretation
Removing prescriptions from Abbott Lingo and other OTC glucose monitors does democratize access. New platforms are already packaging no-prescription glucose tracking with subscriptions and wellness scores, shifting continuous glucose monitoring from clinic-centric to consumer-first products. That is a welcome counter to gatekeeping: you no longer need a doctor’s note to see how your body responds to a heavy dinner or a poor night’s sleep.
But democratization without education is a recipe for confusion. Over-the-counter CGMs are feedback tools, not replacements for clinical diabetes care. For healthy users, “more personal data does not always mean more useful health guidance”. Treating every transient spike as a crisis can encourage unnecessary dietary restriction or anxiety, while chasing perfect flat lines ignores the complexity of metabolism.
The bigger challenge, as one launch analysis notes, is proving that more personal health data leads to better decisions, not just more dashboards. Without clear, evidence-based action steps, metabolic health tracking risks becoming another quantified-self hobby—expensive, time-consuming, and emotionally loaded, with limited payoff beyond novelty.
Data, privacy, and the line between feedback and medicine
Every glucose spike charted on an app lives inside a larger data and AI ecosystem. A CGM is never only a sensor; it brings an app, a cloud account, and terms of service that determine how data is stored, shared, and monetized. Some apps may sit outside traditional medical privacy rules, with different protections depending on whether data stays in a consumer account, enters a provider record, or flows through a wellness program.
Lower-cost, no-prescription CGM access also tempts employers, insurers, and health-tech startups to fold glucose tracking wearables into wellness programs. That could encourage healthier habits—or create subtle pressure to share intimate metabolic profiles in exchange for benefits. Security is another concern; regulators now expect connected health devices to show credible cybersecurity planning, but implementation quality will vary.
For individual users, the practical filter should be blunt: check whether the sensor is FDA cleared, understand what the app does with your glucose data, and treat the numbers as feedback, not medical advice. Over-the-counter glucose monitors can be powerful tools, but only if we remember that they are instruments of observation, not verdicts on our health.
